Looking for markers to predict cancer spread in colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks for biological markers (clues in your body) to predict where colorectal cancer might come back or spread. It aims to help doctors personalize follow-up care and treatment decisions for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You have one of these cancers: colorectal cancer (that has not been treated yet), or primary liver, lung, peritoneal, or bone cancer.
- You have not had any surgery or anti-cancer treatment for this cancer yet.
- You have not had any other type of cancer in the past.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
This study tests if a simple blood test can detect early signs of colorectal cancer coming back after surgery to remove cancer spread in the abdomen. It may help patients avoid unnecessary treatments and catch recurrence sooner.
This study looks at your tumor's genetic makeup and a blood test after surgery to better predict if colorectal cancer that spread to the liver might come back early. The goal is to personalize follow-up care and potentially guide additional treatments.
This study looks at metabolic biomarkers in blood and tumor tissue to help detect colorectal cancer earlier, predict outcomes, and monitor for recurrence. It includes both people newly diagnosed with colorectal cancer and healthy volunteers for comparison.
This study focuses on people with colon cancer (CRC) that has spread to the liver. It looks at factors that may affect liver metastases and could help doctors better understand who may benefit from future treatments.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.